Targeted therapy with favorable efficacy and safety profile

Non-segmental vitiligo is a chronic autoimmune skin disease that requires treatment. Patchy depigmentation on the face and entire body is often associated with a lot of suffering. With ruxolitinib cream, those affected can, for the first time, receive approved topical therapy. If used as directed, the costs are covered by statutory health insurance^B. The selective JAK1 (Janus kinase 1)/JAK2 inhibitor specifically intervenes in the pathomechanism, which can further delay depigmentation and induce repigmentation.